Compare AbbVie Inc (ABBV) vs IONQ Inc (IONQ) Price & Performance

AbbVie IncTrade

IONQ IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs IONQ Inc — how do they compare? AbbVie Inc trades at $249.78 (market cap $441.94B), while IONQ Inc trades at $43.78 (market cap $17.60B). The key difference: AbbVie Inc is far larger — about 25.1× IONQ Inc's market cap, and AbbVie Inc pays a 2.77% dividend while IONQ Inc pays none. Which is the better fit depends on your goals.

	ABBV	IONQ
Market Cap	$441.94B	$17.60B
Sector	Health	Technology
52-Week High	$263.58	$82.09
52-Week Low	$197.38	$26.59
Enterprise Value	$506.19B	$15.53B
Dividend Yield	2.77%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

IONQ Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABBV

Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 23 hours agoNeutral Two Dividend Aristocrats outperformed the market while two lagged; three new picks show promising dividend growth.24/7 Wall Street · 2 days agoNeutral Healthcare sector leads S&P 500 gains over 3 months with key pharma stocks showing strong innovation and income potential.24/7 Wall Street · 2 days agoBullish View details →

IONQ

IonQ outpaces Rigetti with 287% revenue growth and strong outlook, justifying a Buy on IONQ and Sell on RGTI.Seeking Alpha · 1 day agoBullish IonQ posts 287% revenue growth in Q2, beating expectations and boosting 2026 outlookSeeking Alpha · 2 days agoBullish View details →

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

About IONQ Inc

IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.